Regencell Bioscience Investors Urged to Join Securities Fraud Class Action

Investors who incurred significant financial losses holding Regencell Bioscience Holdings Limited shares have until June 23, 2026, to file as lead plaintiffs in a pending securities fraud lawsuit. The Law Offices of Howard G. Smith is currently organizing the class action following allegations of market manipulation and misleading corporate disclosures.

The complaint centers on a period between October 28, 2024, and October 31, 2025. It alleges that Regencell failed to inform shareholders about the company's vulnerability to market manipulation and the resulting volatility that exposed investors to heightened financial risk. These omissions, according to the filing, subjected the firm to increased regulatory scrutiny and potential legal or reputational damage.

Plaintiffs contend that the company’s public statements regarding its business operations and financial health lacked a reasonable basis during the specified timeframe. Investors seeking to discuss their legal rights or participate in the litigation can contact the Law Offices of Howard G. Smith at (215) 638-4847 or via email at [email protected]. Those who choose not to take action remain absent members of the class by default.